BACKGROUND: Human papillomavirus (HPV) RNA detection is reportedly more specific for the detection of anogenital precancer than HPV DNA but it is unknown whether this is due to detection of RNA or due to HPV genotype restriction. METHODS: A total of 363 human immunodeficiency virus (HIV)-positive men who have sex with men had two anal cytology samples taken and were evaluated using high-resolution anoscopy and biopsies of visible lesions. Anal specimens were tested for E6/E7 RNA for five carcinogenic HPV genotypes (HPV16, 18, 31, 33, and 45) and tested for the DNA of 13 carcinogenic HPV genotypes. RESULTS: DNA testing was more likely to be positive than RNA testing (53% vs. 48%; P = 0.02) for the same five HPV genotypes in aggregate. When restricted to five HPV genotypes targeted by the RNA test, the sensitivity to detect anal precancer was the same for DNA and RNA (81%), whereas RNA was more specific than DNA (65% vs. 58%; P = 0.007). In comparison, DNA detection of all 13 carcinogenic HPV genotypes was more sensitive (96% vs. 81%; P = 0.001) but much less specific (65% vs. 33%; P < 0.001) as compared with RNA detection of the five HPV genotypes. CONCLUSION: After controlling for HPV genotypes, RNA was only slightly more specific than DNA detection for anal precancer. IMPACT: DNA or RNA testing for a subset of the most carcinogenic HPV genotypes may be useful for distinguishing between those HPV-positive men at higher and lower risk of anal precancer and cancer.
BACKGROUND:Human papillomavirus (HPV) RNA detection is reportedly more specific for the detection of anogenital precancer than HPV DNA but it is unknown whether this is due to detection of RNA or due to HPV genotype restriction. METHODS: A total of 363 human immunodeficiency virus (HIV)-positive men who have sex with men had two anal cytology samples taken and were evaluated using high-resolution anoscopy and biopsies of visible lesions. Anal specimens were tested for E6/E7 RNA for five carcinogenic HPV genotypes (HPV16, 18, 31, 33, and 45) and tested for the DNA of 13 carcinogenic HPV genotypes. RESULTS: DNA testing was more likely to be positive than RNA testing (53% vs. 48%; P = 0.02) for the same five HPV genotypes in aggregate. When restricted to five HPV genotypes targeted by the RNA test, the sensitivity to detect anal precancer was the same for DNA and RNA (81%), whereas RNA was more specific than DNA (65% vs. 58%; P = 0.007). In comparison, DNA detection of all 13 carcinogenic HPV genotypes was more sensitive (96% vs. 81%; P = 0.001) but much less specific (65% vs. 33%; P < 0.001) as compared with RNA detection of the five HPV genotypes. CONCLUSION: After controlling for HPV genotypes, RNA was only slightly more specific than DNA detection for anal precancer. IMPACT: DNA or RNA testing for a subset of the most carcinogenic HPV genotypes may be useful for distinguishing between those HPV-positive men at higher and lower risk of anal precancer and cancer.
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: CA Cancer J Clin Date: 2012-03-14 Impact factor: 508.702
Authors: Teresa M Darragh; Diane Tokugawa; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Brandon J LaMere; Lauren Schwartz; Julia C Gage; Barbara Fetterman; Thomas Lorey; Nicolas Wentzensen Journal: Cancer Cytopathol Date: 2012-07-18 Impact factor: 5.284
Authors: Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch Journal: Lancet Oncol Date: 2010-10-15 Impact factor: 41.316
Authors: Laurent Gohy; Isabella Gorska; Danielle Rouleau; Georges Ghattas; Alexandra de Pokomandy; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Rachid Hadjeres; Janet R Kornegay; Eduardo Franco; François Coutlée Journal: J Acquir Immune Defic Syndr Date: 2008-09-01 Impact factor: 3.731
Authors: Nicolas Wentzensen; Mark Schiffman; Terence Dunn; Rosemary E Zuna; Michael A Gold; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Joan Walker; Sophia S Wang Journal: Int J Cancer Date: 2009-11-01 Impact factor: 7.396
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: William C Mathews; Edward R Cachay; Joseph Caperna; Amy Sitapati; Bard Cosman; Ian Abramson Journal: PLoS One Date: 2010-08-19 Impact factor: 3.240
Authors: Megan A Clarke; Li C Cheung; Thomas Lorey; Brad Hare; Rebecca Landy; Diane Tokugawa; Julia C Gage; Teresa M Darragh; Philip E Castle; Nicolas Wentzensen Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Lauren M Schwartz; Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Barbara Fetterman; Diane Tokugawa; Thomas S Lorey; Vikrant V Sahasrabuddhe; Patricia Luhn; Julia C Gage; Teresa M Darragh; Nicolas Wentzensen Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Carlos A R Veo; Sarhan S Saad; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Audrey Tieko Tsunoda; Júlio César Possati Resende; Adriana Tarlá Lorenzi; Allini Mafra; Claudia Cinti; Ismael Dale Cotrim; Luciana Albina Reis Rosa; Cristina Mendes de Oliveira; Toni Ricardo Martins; Cristiane Centrone; José Eduardo Levi; Adhemar Longatto-Filho Journal: Tumour Biol Date: 2015-02-13
Authors: Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Nicolas Wentzensen; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Vikrant V Sahasrabuddhe; Jie Chen; Thomas S Lorey; Julia C Gage; Barbara Fetterman; Sean Boyle; Mark Sadorra; Scott Dahai Tang; Teresa M Darragh; Philip E Castle Journal: J Clin Microbiol Date: 2014-06-04 Impact factor: 5.948
Authors: Frank Karlsen; Margaret Muturi; Cosmas Muyabwa; Lars E Roseng; Serge Bigabwa; Byamungu Chihongola; Lucy Muchiri Journal: J Public Health Afr Date: 2018-12-21